Szpital Kliniczny Ministerstwa Spraw Wewnetrznych I Administracji Z Warminsko-Mazurskim Centrum Onkologii W Olsztynie
- Address
- lock Available on a paid plan
Hematologic Malignancies and Blood Disorders
At the Szpital Kliniczny Ministerstwa Spraw Wewnetrznych I Administracji Z Warminsko-Mazurskim Centrum Onkologii W Olsztynie, a major share of research focuses on hematologic cancers and related blood disorders, especially acute myeloid leukemia, lymphomas, chronic lymphocytic leukemia, multiple myeloma, and myelodysplastic syndromes. These studies are designed to test new treatment options, improve disease control, and better support patients with difficult-to-treat or relapsed disease.
- Testing new therapies for diffuse large B-cell lymphoma, Hodgkin lymphoma, and other aggressive lymphomas
- Evaluating treatment strategies for CLL/SLL, multiple myeloma, and myelodysplastic syndromes
- Studying approaches to improve outcomes in anemia and other blood-related complications
This area reflects a strong focus on both cancer treatment innovation and supportive care for patients with complex hematologic conditions.
Solid Tumors in Digestive and Liver Cancers
The site also conducts substantial research in digestive system cancers and liver tumors, including gastric cancer, gastroesophageal junction cancer, colorectal cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, and biliary tract cancer. These trials are mainly aimed at improving survival, slowing disease progression, and identifying better first-line or maintenance treatment options.
- Assessing new combinations for gastric and gastroesophageal junction cancer
- Studying treatment effectiveness in colorectal cancer and esophageal cancer
- Exploring therapies for hepatocellular carcinoma and other advanced liver-related cancers
Research in this field highlights a broad commitment to improving care for patients with advanced gastrointestinal malignancies.
Breast, Ovarian, and Other Female Urogenital Cancers
Clinical trials at this Olsztyn hospital include important work in breast cancer, ovarian cancer, and endometrial cancer, with additional attention to urothelial cancer and bladder cancer. The overall goal is to evaluate new treatment strategies that may improve response, delay recurrence, and offer better options for patients with advanced or high-risk disease.
- Testing therapies for HER2-positive and hormone receptor-positive breast cancer
- Studying treatment options for advanced ovarian cancer and endometrial cancer
- Evaluating new approaches in urothelial cancer and muscle-invasive bladder cancer
This research area combines gynecologic oncology and genitourinary oncology with a focus on better disease control and longer-lasting benefit.
Lung, Head and Neck, and Melanoma Studies
Another key part of the research portfolio centers on thoracic and head and neck cancers, including non-small cell lung cancer, small cell lung cancer, and head and neck squamous cell carcinoma, as well as melanoma. These trials are generally aimed at improving survival, strengthening disease control after standard treatment, and testing more effective combinations for advanced cancer.
- Evaluating new strategies for non-small cell lung cancer and limited-stage small cell lung cancer
- Studying treatment after standard therapy in head and neck cancer
- Testing novel options for melanoma that has returned or spread
This reflects active research in respiratory oncology and difficult-to-treat solid tumors.
Prostate, Myelofibrosis, and Other Specialized Conditions
The site also supports trials in several additional areas, including metastatic prostate cancer, myelofibrosis, acute heart failure, and autoimmune blood disorders. Many of these studies are intended to refine treatment effectiveness, improve symptom control, or address complications linked to cancer and chronic illness.
- Studying treatment options for metastatic hormone-sensitive prostate cancer
- Evaluating therapies for primary and secondary myelofibrosis
- Exploring care approaches for warm autoimmune hemolytic anemia and acute/decompensated heart failure
This mix of research shows the breadth of clinical work at the hospital and oncology center, extending beyond cancer into related internal medicine and supportive care needs.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 16 therapeutic areas and 15 of 114 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 114 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 20 by active trials.
- 1Merck Sharp & Dohme LLC4active
lock +19 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC10trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Szpital Kliniczny Ministerstwa Spraw Wewnetrznych I Administracji Z Warminsko-Mazurskim Centrum Onkologii W Olsztynie
lock Showing 1 of 63 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) | Celgene Corp. | Phase IV | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 114 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 9 | Unknown | 2019-05-20 | 2025-11-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.